Abstract
ABSTRACT
Purpose
In 2014, TriNetX launched a U.S.‐based federated network of health system electronic health records (EHR) that is now used in academic and industry‐sponsored studies and includes more than 250 health care organizations (HCOs) globally. The network expanded to Latin America in 2018, where currently there are over 40 HCO partners in Brazil and Colombia. This manuscript describes the TriNetX LATAM Collaborative Network and outlines how it may support observational studies and clinical trials.
Methods
We queried the LATAM Collaborative Network to determine patient counts for selected disease conditions. We used diagnosis codes, plus drug prescription and/or biometric measures to estimate the frequency of diabetes, hypertension, heart failure, renal impairment, and chronic obstructive pulmonary disease, and estimated survival among patients with breast cancer and prostate cancer.
Results
Approximately 4.54 million patients had at least one healthcare encounter in the data system in 2025; 58.8% of them were female, and 30% were age 60 or older. About 1 million adult patients had a diagnosis of hypertension, prescription of an angiotensin‐converting enzyme inhibitor or angiotensin II antagonist, or systolic blood pressure above 140 mmHg. Among adult patients who had at least one serum estimated glomerular filtration test, 6.7% (43 720 of 655 560) had 2 instances of value 2
} at least 3 months apart. Among 166 490 women with breast cancer, 5‐year survival was 90.7%. Among 116 900 men with prostate cancer, 5‐year survival was 91.1%.
Conclusion
TriNetX LATAM Collaborative Network represents an emerging, scalable EHR‐based data source to support pharmacoepidemiology studies and clinical trials.